Sever Aplastic Anaemia
Conditions
Brief summary
This is a single-dose, open-label, phase I clinical study evaluating the PK of hetrombopag in subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), as well as age-, weight-, and gender-matched subjects with normal hepatic function.
Interventions
Hetrombopag Olamine Tablet
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Sign the informed consent form before the study and fully understand the study content, process, and possible adverse reactions; able to complete the study as required by the clinical study protocol; 2. Subjects (and their partners) are willing to adopt effective contraceptive measures from screening to 6 months after the last study administration. See Appendix 1 for specific contraceptive measures; 3. Aged 18-65 years (inclusive), male or female; 4. Body mass index (BMI = weight (kg)/height2 (m2)): 18-30 kg/m2 (inclusive); 5. For subjects with normal hepatic function: normal or abnormal but not clinically significant laboratory findings (hematology, blood biochemistry, urinalysis, and coagulation function); 6. For subjects with normal hepatic function: no history of severe primary disorders involving major organs, including but not limited to the gastrointestinal, respiratory, renal, hepatic, neural, hematological, endocrine, neoplastic, immunological, psychiatric, or cardiovascular and cerebrovascular disorders. Subjects with hepatic insufficiency must also meet the following inclusion criteria: 7. Have not received medication within 4 weeks before screening, or have received stable medication for at least 4 weeks for hepatic impairment and/or other concurrent diseases requiring long-term treatment; 8. With Child-Pugh Class A or B hepatic insufficiency caused by prior primary liver disorders (except drug-induced liver diseases).
Exclusion criteria
1. Average daily consumption of \> 5 cigarettes within 3 months before screening; 2. Allergic constitution, or allergy to any component of hetrombopag olamine tablets; 3. Average daily alcohol consumption of \> 15 g for females (e.g., 145 mL of wine, 497 mL of beer, or 43 mL of low-alcohol liquor) and \> 25 g for males (e.g., 290 mL of wine, 994 mL of beer, or 86 mL of low-alcohol liquor) within 3 months before screening; 4. History of drug abuse within 3 months before screening; 5. Have donated or lost ≥ 400 mL of blood, or have received blood transfusion within 3 months before screening; 6. Have undergone major surgery within 6 months before screening, or with incomplete healing of surgical incision; 7. History of deep vein thrombosis or other thromboembolic events, or clinical symptoms suggesting thrombophilia; 8. Have received TPO receptor agonists (such as eltrombopag and romiplostim) or TPO within 1 month before screening; 9. Have taken Chinese herbal medicines or any drug that affects the PK of hetrombopag within 14 days before study administration (see Appendix 2 for drug-drug interaction evaluation); 10. Hypertension \[systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg, confirmed by a re-measurement\]; 11. Female subjects who are in lactation or have a positive serum pregnancy test result at screening or during the study; 12. Abnormal and clinically significant 12-lead ECG results (such as tachycardia/bradycardia requiring pharmacological treatment, second- or third-degree atrioventricular block or QTcF interval prolongation (≥ 470 ms for males, ≥ 480 ms for females) (corrected according to Fridericia's formula), or other clinically significant abnormalities assessed by the clinician); 13. Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) equation; 14. Have malignant tumors or history of malignant tumors within 5 years before screening (except treated non-melanoma skin cancer without sign of recurrence and resected cervical intraepithelial neoplasia); 15. For subjects with normal hepatic function: have participated in any drug or medical device clinical trials within 3 months before screening; for subjects with hepatic insufficiency: have participated in any drug or medical device clinical trials within 1 month before screening; 16. For subjects with normal hepatic function: test positive for hepatitis B surface antigen, hepatitis C antibody or hepatitis C core antigen, HIV antibody, or syphilis antibody in screening; 17. Probably undergo surgery or be hospitalized during the study; 18. Have consumed alcohol (or positive for breath alcohol test), grapefruit/grapefruit juice, or any food or beverage containing methylxanthine (such as coffee, tea, cola, chocolate, and energy drink), have participated in strenuous physical activities, or have other factors that may affect drug absorption, distribution, metabolism, and excretion within 1 day before study administration; 19. Positive for urine drug screening (morphine or marijuana); 20. Subjects judged by the investigator as unsuitable for participating in this study. Additional
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak plasma concentration (Cmax) | 0-120 hours post dose |
| Area Under the plasma concentration vs time curve (AUC0-120). | 0-120 hours post dose |
| Area under the blood concentration vs time curve (AUC0-inf). | 0-infinity |
Secondary
| Measure | Time frame |
|---|---|
| Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax) | 0-120 hours post dose |
| Half-life Associated With the Terminal Slope (t½) | 0-120 hours post dose |
| The number of volunteers with adverse events as a measure of safety and tolerability | up to Day 6 |
Countries
China
Outcome results
None listed